FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Microbiol / Whole inactivated equine influenza vaccine: Efficacy against...
Veterinary microbiology2012; 162(2-4); 396-407; doi: 10.1016/j.vetmic.2012.10.019

Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.

Abstract: Equine influenza (EI) is a serious respiratory disease of horses induced by the equine influenza virus (EIV). Surveillance, quarantine procedures and vaccination are widely used to prevent or to contain the disease. This study aimed to further characterise the immune response induced by a non-updated inactivated EI and tetanus vaccine, including protection against a representative EIV isolate of the Florida clade 2 sublineage. Seven ponies were vaccinated twice with Duvaxyn IE-T Plus at an interval of four weeks. Five ponies remained unvaccinated. All ponies were experimentally infected with the EIV strain A/eq/Richmond/1/07 two weeks after the second vaccination. Clinical signs of disease were recorded and virus shedding was measured after experimental infection. Antibody response and EIV-specific IFNgamma synthesis, a marker of cell-mediated immunity, were measured at different time points of the study. Vaccination resulted in significant protection against clinical signs of disease induced by A/eq/Richmond/1/07 and reduced virus shedding when challenged at the peak of immunity. Antigenic drift has been shown to reduce protection against EIV infection. Inclusion of a more recent and representative EIV vaccine strain, as recommended by the OIE expert surveillance panel on equine influenza vaccine, may maximise field protection. In addition, significant levels of EIV-specific IFNgamma synthesis by peripheral blood lymphocytes were detected in immunised ponies, which provided a first evidence of CMI stimulation after vaccination with a whole inactivated EIV. Duration of humoral response was also retrospectively investigated in 14 horses vaccinated under field condition and following the appropriate immunisation schedule, up to 599 days after first immunisation. This study revealed that most immunised horses maintained significant levels of cross-reactive SRH antibody for a prolonged period of time, but individual monitoring may be beneficial to identify poor vaccine responders.
Copyright © 2012 Elsevier B.V. All rights reserved.
Get Full Text
Publication Date: 2012-10-24 PubMed ID: 23146168DOI: 10.1016/j.vetmic.2012.10.019Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research studies the effectiveness of a non-updated inactivated equine influenza vaccine in providing immunity to horses against a specific strain of the equine influenza virus. It indicates that the vaccine offered significant protection against the disease and reduced the amount of virus shed during the peak of immunity. It also triggered significant levels of immune responses, and maintained prolonged levels of cross-reactive antibodies in most immunised horses.

Objective and Methodology

  • The study aimed to understand the immune response induced by a non-updated inactivated equine influenza and tetanus vaccine. It focused on protection the vaccine offers against a specific strain of the equine influenza virus (EIV), namely the Florida clade 2 sublineage.
  • As part of the methodology, seven ponies were vaccinated twice with Duvaxyn IE-T Plus at a four-week interval, while five ponies were left unvaccinated as a control group. Two weeks after the vaccination, all the ponies were experimentally infected with the EIV strain A/eq/Richmond/1/07.

Observations and Findings

  • The study found that vaccination offered significant protection against the clinical signs of the disease induced by the EIV strain and also reduced virus shedding at the peak of immunity.
  • The study also revealed significant levels of EIV-specific IFNgamma synthesis by peripheral blood lymphocytes in vaccinated ponies, providing evidence of cell-mediated immunity (CMI) stimulation after vaccination.
  • The duration of the humoral response was retrospectively investigated in 14 horses vaccinated under field conditions for up to 599 days after immunisation. It was found that most immunised horses maintained significant levels of cross-reactive SRH antibodies for a prolonged period.

Conclusions and Recommendations

  • While the vaccine showed significant levels of protection, the study pointed out that antigenic drift could reduce protection against EIV. It recommended the inclusion of a more recent and representative EIV vaccine strain to maximise field protection.
  • Individual monitoring was recommended to identify poor vaccine responders as it was noted that the response level varied across subjects.

Implications

  • The findings of this study show that while the non-updated inactivated equine influenza vaccine was effective in protecting against a specific strain of EIV, updates to the vaccine might be needed to maximize field protection.
  • The research helps in the understanding of the immune response in horses following vaccination, which is key in managing and preventing outbreaks of equine influenza.

Cite This Article

APA
Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J. (2012). Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity. Vet Microbiol, 162(2-4), 396-407. https://doi.org/10.1016/j.vetmic.2012.10.019

Publication

Veterinary microbiology
ISSN: 1873-2542
NlmUniqueID: 7705469
Country: Netherlands
Language: English
Volume: 162
Issue: 2-4
Pages: 396-407
PII: S0378-1135(12)00558-5

Researcher Affiliations

Paillot, R
  • Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK. Electronic address: romain.paillot@aht.org.uk.
Prowse, L
  • Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK.
Montesso, F
  • Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK.
Huang, C M
  • Eli Lilly and Company, 1301 South White River Parkway East, Indianapolis, IN 46225, USA.
Barnes, H
  • Elanco Animal Health, European Biological R&D Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK.
Escala, J
  • Elanco Animal Health, European Biological R&D Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK.

MeSH Terms

  • Animals
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Antibody Formation / immunology
  • Horse Diseases / immunology
  • Horse Diseases / prevention & control
  • Horses / immunology
  • Immunity, Cellular / immunology
  • Immunity, Humoral / immunology
  • Influenza A Virus, H3N8 Subtype / immunology
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / immunology
  • Interferon-gamma / immunology
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / prevention & control
  • Orthomyxoviridae Infections / veterinary
  • Vaccination / veterinary
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology
  • Virus Shedding / immunology

Citations

This article has been cited 23 times.
  1. Whitlock F, Grewar J, Newton R. An epidemiological overview of the equine influenza epidemic in Great Britain during 2019. Equine Vet J 2023 Jan;55(1):153-164.
    doi: 10.1111/evj.13874pubmed: 36054725google scholar: lookup
  2. Whitlock F, Murcia PR, Newton JR. A Review on Equine Influenza from a Human Influenza Perspective. Viruses 2022 Jun 15;14(6).
    doi: 10.3390/v14061312pubmed: 35746783google scholar: lookup
  3. El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines (Basel) 2022 May 26;10(6).
    doi: 10.3390/vaccines10060855pubmed: 35746463google scholar: lookup
  4. Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM. Equine Influenza Virus and Vaccines. Viruses 2021 Aug 20;13(8).
    doi: 10.3390/v13081657pubmed: 34452521google scholar: lookup
  5. Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W. Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel) 2021 Feb 17;9(2).
    doi: 10.3390/vaccines9020166pubmed: 33671378google scholar: lookup
  6. Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S. Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes. Vaccines (Basel) 2020 Sep 3;8(3).
    doi: 10.3390/vaccines8030501pubmed: 32899189google scholar: lookup
  7. Entenfellner J, Gahan J, Garvey M, Walsh C, Venner M, Cullinane A. Response of Sport Horses to Different Formulations of Equine Influenza Vaccine. Vaccines (Basel) 2020 Jul 10;8(3).
    doi: 10.3390/vaccines8030372pubmed: 32664411google scholar: lookup
  8. Léon A, Castagnet S, Maillard K, Paillot R, Giard JC. Evolution of In Vitro Antimicrobial Susceptibility of Equine Clinical Isolates in France between 2016 and 2019. Animals (Basel) 2020 May 7;10(5).
    doi: 10.3390/ani10050812pubmed: 32392891google scholar: lookup
  9. Cullinane A, Gahan J, Walsh C, Nemoto M, Entenfellner J, Olguin-Perglione C, Garvey M, Huang Fu TQ, Venner M, Yamanaka T, Barrandeguy M, Fernandez CJ. Evaluation of Current Equine Influenza Vaccination Protocols Prior to Shipment, Guided by OIE Standards. Vaccines (Basel) 2020 Feb 29;8(1).
    doi: 10.3390/vaccines8010107pubmed: 32121419google scholar: lookup
  10. Blanco-Lobo P, Rodriguez L, Reedy S, Oladunni FS, Nogales A, Murcia PR, Chambers TM, Martinez-Sobrido L. A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus. Viruses 2019 Oct 11;11(10).
    doi: 10.3390/v11100933pubmed: 31614538google scholar: lookup
  11. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
    doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
  12. Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies. Front Microbiol 2018;9:1941.
    doi: 10.3389/fmicb.2018.01941pubmed: 30237788google scholar: lookup
  13. Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L. The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain. Vaccines (Basel) 2018 Jul 2;6(3).
    doi: 10.3390/vaccines6030038pubmed: 30004410google scholar: lookup
  14. Paillot R, Marcillaud Pitel C, D'Ablon X, Pronost S. Equine Vaccines: How, When and Why? Report of the Vaccinology Session, French Equine Veterinarians Association, 2016, Reims. Vaccines (Basel) 2017 Dec 4;5(4).
    doi: 10.3390/vaccines5040046pubmed: 29207516google scholar: lookup
  15. Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine. Pathogens 2016 Nov 25;5(4).
    doi: 10.3390/pathogens5040064pubmed: 27897990google scholar: lookup
  16. Pavulraj S, Bera BC, Joshi A, Anand T, Virmani M, Vaid RK, Shanmugasundaram K, Gulati BR, Rajukumar K, Singh R, Misri J, Singh RK, Tripathi BN, Virmani N. Pathology of Equine Influenza virus (H3N8) in Murine Model. PLoS One 2015;10(11):e0143094.
    doi: 10.1371/journal.pone.0143094pubmed: 26587990google scholar: lookup
  17. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
    doi: 10.3390/vaccines2040797pubmed: 26344892google scholar: lookup
  18. Bordin AI, Pillai SD, Brake C, Bagley KB, Bourquin JR, Coleman M, Oliveira FN, Mwangi W, McMurray DN, Love CC, Felippe MJ, Cohen ND. Immunogenicity of an electron beam inactivated Rhodococcus equi vaccine in neonatal foals. PLoS One 2014;9(8):e105367.
    doi: 10.1371/journal.pone.0105367pubmed: 25153708google scholar: lookup
  19. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther 2014 Jul 30;5(4):90.
    doi: 10.1186/scrt479pubmed: 25080326google scholar: lookup
  20. Galvin P, Gildea S, Arkins S, Walsh C, Cullinane A. The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA). Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):73-80.
    doi: 10.1111/irv.12195pubmed: 24224822google scholar: lookup
  21. Bordin AI, Suchodolski JS, Markel ME, Weaver KB, Steiner JM, Dowd SE, Pillai S, Cohen ND. Effects of administration of live or inactivated virulent Rhodococccus equi and age on the fecal microbiome of neonatal foals. PLoS One 2013;8(6):e66640.
    doi: 10.1371/journal.pone.0066640pubmed: 23785508google scholar: lookup
  22. Atwa AS, Gomaa L, Elmenofy W, Amer HM, Ahmed BM. Expression of recombinant Florida clade 2 hemagglutinin in baculovirus expression system: A step for subunit vaccine development against H3N8 equine influenza virus. Open Vet J 2024 Jan;14(1):350-359.
    doi: 10.5455/OVJ.2024.v14.i1.32pubmed: 38633177google scholar: lookup
  23. Elliott S, Olufemi OT, Daly JM. Systematic Review of Equine Influenza A Virus Vaccine Studies and Meta-Analysis of Vaccine Efficacy. Viruses 2023 Nov 28;15(12).
    doi: 10.3390/v15122337pubmed: 38140577google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.